Brookfield Infrastructure Partners LP vs Nuwellis Inc — how do they compare? Brookfield Infrastructure Partners LP trades at $38.19 (market cap $17.38B), while Nuwellis Inc trades at $3.16 (market cap $1.17M). The key difference: Brookfield Infrastructure Partners LP is far larger — about 14854.7× Nuwellis Inc's market cap, and Brookfield Infrastructure Partners LP pays a 4.77% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| BIP | NUWE | |
|---|---|---|
Market Cap | $17.38B | $1.17M |
Sector | Industrials | Technology |
52-Week High | $40.08 | $558.26 |
52-Week Low | $29.81 | $2.80 |
Enterprise Value | $79.06B | -$636.97K |
Dividend Yield | 4.77% | — |
Signals from Pluang's Aura AI — not financial advice
Brookfield Infrastructure Partners (BIP) trades at $37.61, down slightly by 0.11% today. The stock shows bullish technical signals with strong analyst support (81% buy ratings) and a $45.50 consensus price target. Recent earnings have been mixed with one beat and two misses, but the company maintains robust cash flows with $5.97B from operations in 2025. BIP offers a 5% dividend yield with recent H1-26 payment of $0.46 per share.
BIP presents a compelling value opportunity with discounted valuation metrics (P/S 0.73, EV/EBITDA 7.55) and strong infrastructure assets. However, investors face risks from recent earnings volatility, high P/E ratio of 57.8, and declining profit margins. The company's global infrastructure portfolio provides inflation protection and stable cash flows, supporting the bullish analyst consensus despite near-term headwinds.
NUWE trades at $2.80, down 7.89% in the last session, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025 despite $8.27M revenue, reflecting negative profit margins and cash flow challenges. Recent news highlights expansion in pediatric care and a $6M public offering closed in June 2026, alongside a CEO transition to Mike McCormick effective June 30, 2026.
Outlook remains high-risk due to persistent losses and cash burn, though analyst consensus is split evenly between Buy and Hold. Key risks include execution in revenue growth and reliance on financing. Upside depends on successful commercialization of Aquadex therapy and FDA label expansion for pediatric patients.
Trailing returns across standard periods
Latest headlines on both assets
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →